留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

抗磷脂综合征相关循环系统表现

张金 李程 韩笑蓉 陈中波 王英慧 王宏 王永刚

张金, 李程, 韩笑蓉, 陈中波, 王英慧, 王宏, 王永刚. 抗磷脂综合征相关循环系统表现[J]. 中华全科医学, 2021, 19(9): 1557-1561. doi: 10.16766/j.cnki.issn.1674-4152.002111
引用本文: 张金, 李程, 韩笑蓉, 陈中波, 王英慧, 王宏, 王永刚. 抗磷脂综合征相关循环系统表现[J]. 中华全科医学, 2021, 19(9): 1557-1561. doi: 10.16766/j.cnki.issn.1674-4152.002111
ZHANG Jin, LI Cheng, HAN Xiao-rong, CHEN Zhong-bo, WANG Ying-hui, WANG Hong, WANG Yong-gang. Circulatory system manifestations of antiphospholipid antibody syndrome[J]. Chinese Journal of General Practice, 2021, 19(9): 1557-1561. doi: 10.16766/j.cnki.issn.1674-4152.002111
Citation: ZHANG Jin, LI Cheng, HAN Xiao-rong, CHEN Zhong-bo, WANG Ying-hui, WANG Hong, WANG Yong-gang. Circulatory system manifestations of antiphospholipid antibody syndrome[J]. Chinese Journal of General Practice, 2021, 19(9): 1557-1561. doi: 10.16766/j.cnki.issn.1674-4152.002111

抗磷脂综合征相关循环系统表现

doi: 10.16766/j.cnki.issn.1674-4152.002111
基金项目: 

吉林省科技发展计划基金项目 20190701066GH

吉林省教委科研基金项目 JJKH20201046KJ

详细信息
    通讯作者:

    王永刚,E-mail: xiaogang94@163.com

  • 中图分类号: R593.2  R542.5

Circulatory system manifestations of antiphospholipid antibody syndrome

  • 摘要: 抗磷脂综合征是一种自身免疫性疾病, 其特征是血液中的抗磷脂抗体持续阳性, 与血栓形成、流产等疾病发生风险相关。目前抗磷脂综合征的诊断是基于符合最新札幌分类标准中至少一项临床表现和至少一项临床实验室标准。目前抗磷脂综合征越来越被认为是一种多器官、多系统疾病, 其临床表现谱正逐渐扩大, 可累及不同的器官系统, 循环系统是抗磷脂综合征主要累及的靶器官系统之一。抗磷脂综合征相关循环系统表现的发病机制主要在2个方面, 即自身免疫和血栓形成。常见的循环系统受累的临床表现包括血栓形成、心脏瓣膜病、缺血性心肌病、动脉粥样硬化、肺高压以及心室功能不全等。血管超声检查、超声心动图、计算机断层扫描、磁共振成像、核医学检查等非侵入性影像学检查技术是抗磷脂综合征相关循环系统表现的首选检查方法, 冠状动脉造影等有创心脏检查会加剧血栓形成风险, 不建议作为常规检查手段。抗凝是抗磷脂综合征患者治疗的基础, 抗凝方案应基于抗磷脂综合征患者的危险分层进行选择。对于抗磷脂综合征患者是否可行经皮冠状动脉介入治疗及外科手术治疗等有创治疗目前仍存在争议。本文对抗磷脂综合征患者可能出现的相关循环系统表现及其发病机制、影像学检查、治疗策略进行阐述。

     

  • [1] SAMMARITANA L R. Antiphospholipid syndrome[J]. Best Pract Res Clin Rheumatol, 2020, 34(1): 101463. doi: 10.1016/j.berh.2019.101463
    [2] 王斌, 黄劲, 唐宁, 等. 554例抗磷脂抗体阳性病例的临床分析[J]. 国际检验医学杂志, 2017, 38(22): 3185-3187. doi: 10.3969/j.issn.1673-4130.2017.22.043
    [3] 张书筠, 张弘, 王云洁, 等. 低分子肝素联合阿司匹林治疗抗磷脂抗体引起的复发性流产的临床效果分析[J]. 河北医学, 2018, 24(3): 422-426. doi: 10.3969/j.issn.1006-6233.2018.03.019
    [4] PETRI M. Antiphospholipid syndrome[J]. Transl Res, 2020, 225: 70-81. doi: 10.1016/j.trsl.2020.04.006
    [5] KOLITZ T, SHIBER S, SHARABI I, et al. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form[J]. Front Immunol, 2019, 10: 941. doi: 10.3389/fimmu.2019.00941
    [6] DUARTE-GARCÍA A, PHAM M M, CROWSON C S, et al. The epidemiology of antiphospholipid syndrome: A population-based study[J]. Arthritis Rheumatol, 2019, 71(9): 1545-1552. doi: 10.1002/art.40901
    [7] ZARATZIAN C, GOURIET F, TISSOT-DUPONT H, et al. Antiphospholipid antibodies proposed in the diagnosis of infective endocarditis[J]. Eur J Clin MicrobiolInfect Dis, 2017, 36(7): 1159-1162. doi: 10.1007/s10096-017-2903-1
    [8] GARCIA D, ERKAN D. Diagnosis and management of the antiphospholipid syndrome[J]. N Engl J Med, 2018, 378(21): 2010-2021. doi: 10.1056/NEJMra1705454
    [9] ROOT-BERNSTEIN R. Synergistic activation of Toll-Like and NOD receptors by complementary antigens as facilitators of autoimmune disease: Review, model and novel predictions[J]. Int J Mol Sci, 2020, 21(13): 4645. doi: 10.3390/ijms21134645
    [10] SULE G, KELLEY W J, GOCKMAN K, et al. Increased adhesive potential of antiphospholipid syndrome neutrophils mediated by β2 integrin Mac-1[J]. Arthritis Rheumatol, 2020, 72(1): 114-124. doi: 10.1002/art.41057
    [11] CHEN J Q, PAPP G, SZODORAY P, et al. The role of microRNAs in the pathogenesis of autoimmune diseases[J]. Autoimmun Rev, 2016, 15(12): 1171-1180. doi: 10.1016/j.autrev.2016.09.003
    [12] BAE S-C, LEE Y H. Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis: A meta-analysis[J]. Z Rheumatol, 2020, 79(3): 312-318. doi: 10.1007/s00393-019-00689-y
    [13] MAVROGENI S I, SFIKAKIS P P, KITAS G D, et al. Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging[J]. Semin Arthritis Rheum, 2016, 45(5): 611-616. doi: 10.1016/j.semarthrit.2015.09.005
    [14] TEKTONIDOU M G, ANDREOLI L, LIMPER M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults[J]. Ann Rheum Dis, 2019, 78(10): 1296-1304. doi: 10.1136/annrheumdis-2019-215213
    [15] CHIGHIZOLA C B, RAIMONDO M G, MERONI P L. Management of thrombotic antiphospholipid syndrome[J]. Semin Thromb Hemost, 2018, 44(5): 419-426. doi: 10.1055/s-0036-1597282
    [16] BURNETT A E, MAHAN C E, VAZQUEZ S R, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment[J]. J Thromb Thrombolysis, 2016, 41(1): 206-232. doi: 10.1007/s11239-015-1310-7
    [17] BALA M M, CELINSKA-LOWENHOFF M, SZOT W, et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic eventsin people with antiphospholipid syndrome[J]. Cochrane Database Syst Rev, 2017, 10(10): CD012169. doi: 10.1002/14651858.cd012169.pub2
    [18] COHEN H, HUNT B J, EFTHYMIOU M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2/3, non-inferiority trial[J]. Lancet Haematol, 2016, 3(9): e426-436. doi: 10.1016/S2352-3026(16)30079-5
    [19] WOLLER S C, STEVENS S M, KAPLAN D A, et al. Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study[J]. Clin Appl Thromb Hemost, 2018, 24(1): 192. doi: 10.1177/1076029617729214
    [20] DUFROST V, RISSE J, RESHETNYAK T, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis[J]. Autoimmun Rev, 2018, 17(10): 1011-1021. doi: 10.1016/j.autrev.2018.04.009
    [21] CHIGHIZOLA C B, MERONI P L. Thrombosis and anti-phospholipid syndrome: A 5-Year Update on Treatment[J]. Curr Rheumatol Rep, 2018, 20(7): 44. doi: 10.1007/s11926-018-0741-5
    [22] WAISAYARAT J, PLUMWORASAWAT S, VILAIYUK S, et al. Intracardiac thrombus in a patient with catastrophic antiphospholipid syndrome: An autopsy case report and review of the literature[J]. Vasc Health Risk Manag, 2019, 15: 253-258. doi: 10.2147/VHRM.S197638
    [23] YEH J J, WANG Y C, CHEN J H, et al. Effect of systemic lupus erythematosus on therisk of incident respiratory failure: A national cohort study[J]. PLoS One, 2016, 11(9): e0163382. doi: 10.1371/journal.pone.0163382
    [24] GALIÈ N, HUMBERT M, VACHIERY J L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Rev Esp Cardiol(Engl Ed), 2016, 69(2): 177.
    [25] CORBAN M T, DUARTE-GARCIA A, MCBANE R D, et al. Antiphospholipid syndrome: Role of vascular endothelial cells and implications for risk stratification and targeted therapeutics[J]. J Am Coll Cardiol, 2017, 69(18): 2317-2330. doi: 10.1016/j.jacc.2017.02.058
    [26] KIM N H, DELCROIX M, JAIS X, et al. Chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2019, 53(1): 1801915. doi: 10.1183/13993003.01915-2018
    [27] PARTHVI R, SIKACHI R R, AGRAWAL A, et al. Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?[J]. Intractable Rare Dis Res, 2017, 6(3): 163-171. doi: 10.5582/irdr.2017.01044
    [28] GHOFRANI H A, GRVNIG E, JANSA P, et al. Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension(PATENT studies)[J]. Pulm Circ, 2020, 10(3): 2045894020942121. http://www.researchgate.net/publication/342998158_Efficacy_and_safety_of_riociguat_in_combination_therapy_for_patients_with_pulmonary_arterial_hypertension_PATENT_studies
    [29] WEAVER J C, KRILIS S A, GIANNAKOPOULOS B. Oxidative post-translational modification of beta 2-glycoprotein I in the pathophysiology of the anti-phospholipid syndrome[J]. Free Radic Biol Med, 2018, 125: 98-103. doi: 10.1016/j.freeradbiomed.2018.03.048
    [30] PÉREZ-SÁNCHEZ C, AGUIRRE M A, RUIZ-LIMÓN P, et al. Atherothrombosis-associated microRNAs in antiphospholipid syndrome and systemic lupus erythematosus patients[J]. Sci Rep, 2016, 6: 31375. doi: 10.1038/srep31375
    [31] BENAGIANO M, GEROSA M, ROMAGNOLI J, et al. β2 glycoprotein I recognitiondrives Th1 inflammation in atherosclerotic plaques of patients with primaryantiphospholipid syndrome[J]. J Immunol, 2017, 198(7): 2640-2648. doi: 10.4049/jimmunol.1600305
    [32] URBANUS R T. Recent developments in antiphospholipid antibodies and the antiphospholipid syndrome[J]. Semin Thromb Hemost, 2018, 44(5): 417-418. doi: 10.1055/s-0038-1657761
    [33] BUNDHUN P K, BOODHOO K D, LONG M Y, et al. Impact of antiphospholipid syndrome and/or systemic lupus erythematosus on the long-term adverse cardiovascular outcomes in patients after percutaneous coronary intervention: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2016, 95(12): e3200. doi: 10.1097/MD.0000000000003200
    [34] CHIGHIZOLA C B, SCIASCIA S, ANDREOLI L, et al. Beyond current concepts in anti-phospholipid syndrome: The 16th international congress on anti-phospholipid antibodies(ICAPA)in Manchester[J]. Autoimmun Rev, 2020, 19(9): 102615. doi: 10.1016/j.autrev.2020.102615
    [35] GENERALI E, FOLCI M, SELMI C, et al. Immune-mediated heart disease[J]. Adv Exp Med Biol, 2017, 1003: 145-171.
    [36] ZUILY S. Heart valve involvement in antiphospholipid syndrome: More than you think![J]. Int J Cardiol, 2019, 284: 96-97. doi: 10.1016/j.ijcard.2018.10.021
    [37] TUFANO A, DI MINNO M N D, GUIDA A, et al. Cardiac manifestations of antiphospholipid syndrome: Clinical presentation, role of cardiac imaging, and treatment strategies[J]. Semin Thromb Hemost, 2019, 45(5): 468-477. doi: 10.1055/s-0039-1692702
    [38] CHANG J C, WHITE B R, ELIAS M D, et al. Echocardiographic assessment of diastolic function in children with incident systemic lupus erythematosus[J]. Pediatr Cardiol, 2019, 40(5): 1017-1025. doi: 10.1007/s00246-019-02107-1
    [39] NAGUEH S F, SMISETH O A, APPLETON C P, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. Eur Heart J Cardiovasc Imaging, 2016, 17(12): 1321-1360. doi: 10.1093/ehjci/jew082
    [40] TUFANO A, LEMBO M, DI MINNO M N, et al. Left ventricular diastolic abnormalities other thanvalvular heart disease in antiphospholipid syndrome: An echocardiographic study[J]. Int J Cardiol, 2018, 271: 366-370. doi: 10.1016/j.ijcard.2018.05.040
  • 加载中
计量
  • 文章访问数:  101
  • HTML全文浏览量:  52
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-07-10
  • 网络出版日期:  2022-02-15

目录

    /

    返回文章
    返回